CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Status:
RECRUITING
Trial end date:
2029-03-27
Target enrollment:
Participant gender:
Summary
1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma.
2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China